Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Recent progress in P-glycoprotein research.

K Ueda1, A Yoshida, T Amachi

  • 1Laboratory of Biochemistry, Division of Applied Life Sciences, Kyoto University Graduate School of Agriculture, Japan.

Anti-Cancer Drug Design
|July 16, 1999
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

HPC-1 is associated with synaptotagmin and omega-conotoxin receptor.

The Journal of biological chemistry·1992
Same author

[The first cholera case diagnosed early in the clinical laboratory by DNA probe method].

Kansenshogaku zasshi. The Journal of the Japanese Association for Infectious Diseases·1992
Same author

Parathyroid hormone inhibits immunoglobulin production without affecting cell growth in human B cells.

Clinical immunology and immunopathology·1992
Same author

Structural differences between heparan sulphates of proteoglycan involved in the formation of basement membranes in vivo by Lewis-lung-carcinoma-derived cloned cells with different metastatic potentials.

The Biochemical journal·1992
Same author

The quality and quantity of dietary protein affect brain protein synthesis in rats.

The Journal of nutrition·1992
Same author

Evaluation of thyroid function in patients with isolated adrenocorticotropin deficiency.

The American journal of the medical sciences·1992
Same journal

Topoisomerase I/II selectivity among derivatives of N-[2-(dimethylamino)ethyl]acridine-4-carboxamide (DACA).

Anti-cancer drug design·2002
Same journal

Linker length in podophyllotoxin-acridine conjugates determines potency in vivo and in vitro as well as specificity against MDR cell lines.

Anti-cancer drug design·2002
Same journal

The inhibition of protein phosphatases 1 and 2A: a new target for rational anti-cancer drug design?

Anti-cancer drug design·2002
Same journal

Photokilling of cultured tumour cells by the porphyrin derivative CF3.

Anti-cancer drug design·2002
Same journal

Cyclohexylamino-demethoxy-hypocrellin B and photodynamic therapy decreases human cancer in vitro.

Anti-cancer drug design·2002
Same journal

Synthesis and anticancer activity of nordihydroguaiaretic acid (NDGA) and analogues.

Anti-cancer drug design·2002
See all related articles

P-glycoprotein, a key factor in multidrug resistance, extrudes toxic compounds from cells. Research is advancing on its structure, transport mechanisms, and therapeutic strategies like gene therapy using the MDR1 gene.

Area of Science:

  • Biochemistry
  • Molecular Biology
  • Pharmacology

Background:

  • P-glycoprotein (P-gp) is a crucial xenobiotic transporter implicated in multidrug resistance (MDR) in cancer.
  • Its ability to efflux diverse toxic compounds contributes to therapeutic failure in oncology.

Purpose of the Study:

  • To review recent advancements in understanding P-glycoprotein's structure and function.
  • To discuss substrate recognition and transport mechanisms.
  • To explore modulators of MDR and gene therapy approaches targeting the MDR1 gene.

Main Methods:

  • Literature review of recent research on P-glycoprotein.
  • Analysis of studies on P-gp structure and substrate binding.
  • Examination of therapeutic strategies for overcoming MDR.

Related Experiment Videos

Main Results:

  • P-glycoprotein's diverse substrate binding sites and transport mechanisms are increasingly elucidated.
  • Specific modulators targeting P-gp function show promise in preclinical studies.
  • Gene therapy strategies involving the MDR1 gene are under investigation for MDR reversal.

Conclusions:

  • Continued research into P-glycoprotein structure and function is vital for developing effective MDR therapies.
  • Targeting P-glycoprotein and exploring MDR1 gene-based therapies represent promising avenues for improving cancer treatment outcomes.